LiveLunger has created LungBeat, a CE-marked medical app designed to support chronic respiratory patients in their daily asthma self-management. LungBeat utilizes a Bluetooth-connected spirometer connection, providing regular insights into your current lung capacity.

If you experience any complaints at home or notice changes in your symptoms, simply answer three questions, and LungBeat will guide you on which personalized action plan to follow.

Patients

LungBeat developed by LiveLunger, is designed for asthma patients and their families. It provides peace of mind, knowing that you have a digital assistant to guide you on how you feel. Additionally, LungBeat offers a direct link to your care team.

Health care professionals

LiveLunger’s LungBeat is developed for asthma patients and their family. It offers them a digital assistent closeby to consult in between face-to-face consultations in the hospital. Like this, healthcare professionals, can build on more continuous data streams and can have insights into how the patients are doing when they are at home, in between consultations.

Moreover, we are looking for clinical partnerships to extend LungBeat with features that can increase the power of telemonitoring in a meaningful clinical way.

Interested in running a clinical pilot with LungBeat?

Health Insurance Fund

Within your client base 3-5% experience severe asthma and receive biological therapies. These treatments are costly and necessitate strict adherence to medication plans. Clinical studies have demonstrated that LungBeat enhances the patients’ therapy adherence rates.  Maintaining adherence to therapy not only improves daily outcomes and quality of life for patients but also contributes to cost savings for social security and health insurance funds.

Interested in adding LungBeat to your member portfolio?

Pharmaceutical companies

Among your clients 3-5% suffer from severe asthma and receive biological therapies. These therapies are expensive and require a patient to be strictly compliant to medication plans. Clinical studies have shown that LungBeat improves the therapy adherence rate of patients. This can significantly impact the outcome of clinical trials for novel asthma therapies. Moreover, we are looking for partnerships to move LungBeat beyond asthma into other respiratory domains.

Interested in discussing the potential of LungBeat for your clinical development?

LungBeat, already a CE approved working product aims to expand its capabilities across various domains:

• Predictive Insights: Enhancing LungBeat’s predictive capabilities will allow it to anticipate when a patient’s condition may worsen. By analyzing historical data and patterns, it can provide timely alerts and personalized recommendations.
• Weather and Climate Integration: Linking LungBeat to weather and climate conditions enables a holistic approach to respiratory care. Patients can receive context-aware advice based on environmental factors that impact their symptoms.
• Diagnostic Capabilities: Integrating clinical parameters into LungBeat will enhance its diagnostic abilities. By analyzing data such as lung function, inflammation markers, and symptom severity, it can assist in early detection and personalized treatment planning.